SCHEMBL31014394

SCHEMBL31014394

COc1cncc(/C(Cl)=N/O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 2/20 0.41
MKNK1 Q9BUB5 1/20 0.41
CYP11B1 P15538 5/20 0.38
CYP11B2 P19099 5/20 0.38
CYP3A4 P08684 3/20 0.38
CYP1A2 P05177 2/20 0.38
ROCK2 O75116 1/20 0.38
MAP4K4 O95819 1/20 0.38
PRKACA P17612 1/20 0.38
ROCK1 Q13464 1/20 0.38
DYRK1A Q13627 1/20 0.38
NTRK3 Q16288 1/20 0.38
PKN2 Q16513 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
STK17A Q9UEE5 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALDH1A1 P00352 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP1A1 P04798 1/20 0.37
CYP1B1 Q16678 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14395859 1.00 MKNK2 (0.41) MKNK2MKNK1CYP11B1CYP11B2CYP3A4
SCHEMBL14755452 0.80 MKNK2 (0.46) MKNK2MKNK1CYP11B1CYP11B2CYP3A4
SCHEMBL31192058 0.80 MKNK2 (0.46) MKNK2MKNK1CYP11B1CYP11B2CYP3A4
SCHEMBL4187225 0.79 MKNK2 (0.49) MKNK2MKNK1CYP11B1CYP11B2CYP3A4
Hydrochloric Acid SCHEMBL3821290 0.78 MKNK2 (0.47) MKNK2MKNK1CYP11B1CYP11B2CYP3A4
SCHEMBL20419469 0.75 ATM (0.59) CYP11B1CYP11B2CYP2C9ALDH1A1TDP1
SCHEMBL2121043 0.74 NPC1 (0.58) SMN1; SMN2
SCHEMBL2121044 0.74 NPC1 (0.58) SMN1; SMN2
SCHEMBL8252989 0.74 NPC1 (0.58) SMN1; SMN2
SCHEMBL3209723 0.73 CYP11B1 (0.58) MKNK2MKNK1CYP11B1CYP11B2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 US disclosed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 US disclosed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 MKNK2 3027/4885MKNK1 2909/4885CYP11B1 3658/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 MKNK2 3027/4885MKNK1 2909/4885CYP11B1 3658/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 MKNK2 3027/4885MKNK1 2909/4885CYP11B1 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.